| 0.1698 -0.008 (-4.61%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.22 | 1-year : | 0.24 |
| Resists | First : | 0.18 | Second : | 0.2 |
| Pivot price | 0.16 |
|||
| Supports | First : | 0.15 | Second : | 0.13 |
| MAs | MA(5) : | 0.17 |
MA(20) : | 0.16 |
| MA(100) : | 0.2 |
MA(250) : | 0.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57 |
D(3) : | 45.8 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 2.79 | Low : | 0.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RSLS ] has closed below upper band by 37.4%. Bollinger Bands are 75.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.18 - 0.18 | 0.18 - 0.18 |
| Low: | 0.17 - 0.17 | 0.17 - 0.17 |
| Close: | 0.17 - 0.17 | 0.17 - 0.17 |
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Wed, 03 Apr 2024
ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Mon, 01 Apr 2024
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Mon, 04 Mar 2024
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize ... - GlobeNewswire
Wed, 20 Dec 2023
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives - Yahoo Finance
Wed, 13 Dec 2023
ReShape Lifesciences stock soars as obesity treatment gets FDA greenlight - Proactive Investors UK
Wed, 13 Dec 2023
Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 23 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 11.1 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 729 (K) |
| Shares Short P.Month | 756 (K) |
| EPS | -1.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | -131.3 % |
| Operating Margin | -95.7 % |
| Return on Assets (ttm) | -84 % |
| Return on Equity (ttm) | -220.6 % |
| Qtrly Rev. Growth | -36.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.09 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0.45 |
| Price to Cash Flow | -0.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|